Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases.
Headquartered in Denmark, Novo Nordisk employs approximately 43,100 people in 79 countries and markets its products in more than 170 countries.
This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam.
Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: http://novonordisk.com/about_us/global_offices/global_offices.asp.
For other customer complaints please contact us here: http://novonordisk.com/about_us/contact_us/contact_us.asp
Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industries. Therefore, comments that pertain to legal matters or regulatory issues may be removed.
Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other Linkedin users.
Learn more about our privacy disclaimer and community guidelines here http://bit.ly/2LsaqW8